Join to View Full Profile
1611 NW 12th AveMiami, FL 33136
Phone+1 305-585-1111
Dr. Merchan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Harvard University - Massachusetts Institute of TechnologyMMSc, Translational Research, 2001 - 2003
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
University of Miami/Jackson Health SystemResidency, Internal Medicine, 1994 - 1998
Universidad Catolica de Santiago de GuayaquilClass of 1992
Certifications & Licensure
FL State Medical License 1997 - 2028
MN State Medical License 2003 - 2007
MA State Medical License 1998 - 2005
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017
Clinical Trials
- Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors Start of enrollment: 2008 Nov 01
- Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy Start of enrollment: 2016 Jan 05
- Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors Start of enrollment: 2017 Apr 17
Publications & Presentations
PubMed
- Metabolomic Insights Into Saliva as a Non-Invasive Surrogate for Serum to Enable Community-Based Biomarker Investigation.Alireza Abdshah, Mohammad Alyamani, Robert A Burgess, Dipen J Parekh, Benjamin Spieler
The Prostate. 2026-05-01 - Oncolytic Virotherapy for Solid Tumors: Clinical Advances and Future Directions.Palash Asawa, Xena Zheng, Jaime Rafael Merchan
Surgical Oncology Clinics of North America. 2026-04-01 - MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors.Ecaterina Dumbrava, Anna Minchom, Jason Henry, Melissa Johnson, David Sommerhalder
Future Oncology. 2026-02-01
Journal Articles
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell CarcinomaRobert Motzer, Thomas E Hutson, Jaime R Merchan, Corina E Dutcus, Rodolfo F Perini, Toni K Choueiri, The New England Journal of Medicine
Lectures
- Toca 6: A phase 1b study of Toca 511 and Toca FC in patients with advanced solid tumors or lymphoma.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Other
- Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiencyMerchan JR
http://www.uptodate.com/contents/chemotherapy-related-nephrotoxicity-and-dose-modification-in-patien
UpToDate, Wolters Kluwer Health - 2013-02-05
Authored Content
- Notch Pathway Inhibition with LY3039478 in Soft Tissue Sarcoma and Gastrointestinal Stromal TumoursOctober 2018
Press Mentions
May 2025 Sylvester Cancer Insights: Essential Tips and UpdatesMay 19th, 2025- Sylvester Cancer Tip Sheet - May 2025May 17th, 2025
- Sylvester Comprehensive Cancer Center Unveils Key Insights for ASCO 2025May 1st, 2025
Grant Support
- Tumor And Stromal Targeting By Oncolytic VirusesNational Cancer Institute2011–2012
- Biomarkers For VEGF And Mtor Blockade In Advanced Renal CancerNational Cancer Institute2006–2007
Professional Memberships
- Member
- Member
Other Languages
- Spanish, Portuguese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
